Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Total Current Liabilities data on file, last reported at $129.7 million in Q1 2026.

• Quarterly Total Current Liabilities fell 8.65% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.7 million (down 8.65% YoY) and the FY2025 annual result came in at $147.7 million, down 21.21% from the prior year.
• Total Current Liabilities eased to $129.7 million in Q1 2026, from $147.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $187.5 million in Q4 2024 to a low of $73.9 million in Q1 2024.
• A 5-year average of $114.9 million and a median of $100.3 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 227.19% — and 2024, when it declined 24.46%.
• Tracing RXRX's Total Current Liabilities over 5 years: stood at $100.3 million in 2022, then declined by 7.08% to $93.2 million in 2023, then soared by 101.21% to $187.5 million in 2024, then fell by 21.21% to $147.7 million in 2025, then declined by 12.19% to $129.7 million in 2026.
• The last three Total Current Liabilities figures came in at $129.7 million (Q1 2026), $147.7 million (Q4 2025), and $155.1 million (Q3 2025), per Business Quant data.